Controlling Shareholder Richard Griffiths Sells $87.7M in ADSs, Stake Falls to 7.97%
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (3.2× avg).
Summary
Controlling shareholder Richard Griffiths sold $87.7 million in ADSs, cutting his stake from 21.7% to 7.97% amid the company's $175 million offering.
Key Events · Ownership and Investor Activity · SLN
-
Controlling Shareholder Sells $87.7M
Richard Griffiths sold 5,484,320 ADSs between August 10-12, 2026 for aggregate proceeds of $87.7 million.
-
Stake Falls to 7.97%
Griffiths' ownership dropped from 21.7% to 7.97% of outstanding ordinary shares, reflecting both the sales and dilution from the $175 million offering.
-
Sales Coincide with Offering
The sales occurred immediately after positive Phase 2 data for divesiran and concurrent with the company's upsized public offering priced at $13.50 per ADS.
-
Loss of Controlling Position
Griffiths is no longer the controlling shareholder, a significant governance change for the company.
Analysis · SLN · Life Sciences
A significant governance shift unfolds as Richard Griffiths, the controlling shareholder, sells 5,484,320 ADSs for $87.7 million between August 10-12, 2026, reducing his stake from 21.7% to 7.97%. The sales come immediately after the company's positive Phase 2 data for divesiran and concurrent with the $175 million public offering priced at $13.50 per ADS. The stake reduction reflects both the open market sales and dilution from the offering. Griffiths' exit from a controlling position is a significant governance event, as he was the largest shareholder and a director.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $641.6M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.